ArticleThe EPMA journal2025
Pyridoxal 5'-phosphate and risk of stroke: triangulation of evidence from a nationally representative cohort and bidirectional Mendelian randomization analysis.
Article in The EPMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke is a leading cause of mortality and disability worldwide. Identifying predictive biomarkers and modifiable risk factors is crucial for stroke prevention in the context of predictive, preventive, and personalized medicine (PPPM). We aimed to investigate the association of serum pyridoxal 5'-phosphate (PLP) levels with stroke prevalence in a nationally representative cohort and to assess the causal relationship using bidirectional Mendelian randomization (MR) analysis, with a focus on the implications for PPPM strategies in stroke management. Methods: We included 6839 participants aged ≥ 18 years from the National Health and Nutrition Examination Survey (NHANES) 2005-2013. Serum PLP levels were measured by high-performance liquid chromatography. Stroke prevalence was ascertained by self-report. We used generalized linear models, Kaplan-Meier curves, restricted cubic splines, stratified analysis, receiver operating characteristic (ROC) curves, and bidirectional two-sample MR to examine the association of PLP levels with stroke prevalence and assess the causal relationship. Results: In the fully adjusted model, participants with low serum PLP levels had significantly higher odds of stroke compared to those with high levels (odds ratio (OR) = 6.51e-01, 95% confidence interval (CI) 4.46e-01-9.50e-01, Conclusions: Low serum PLP levels are significantly associated with higher stroke prevalence in a nationally representative the United States (US) sample. Integration of observational and genetic evidence supports a protective causal role of PLP in stroke risk. Serum PLP may serve as a promising predictive biomarker for stroke risk assessment and a potential target for personalized nutritional interventions in stroke prevention, in line with PPPM strategies. Our findings highlight the importance of maintaining optimal vitamin B6 status for effective PPPM-guided stroke prevention and management. Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-024-00392-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.